Market
Magnesium oxide in Brazil is used primarily as a mineral-source constituent in dietary supplements and also appears as an excipient/active in pharmaceutical contexts. For supplements, Brazil’s framework requires that only Anvisa-authorized constituents be used, and magnesium oxide is listed among authorized magnesium sources. Ingredient identity/purity/composition must align with recognized specifications (including the Farmacopeia Brasileira) and documentation must be available for competent authority review. Imports and domestic handling commonly route through Brazil’s Portal Único (Siscomex) processes with Anvisa participation for food-related petitions.
Market RoleDomestic supplement manufacturing and consumer market (imported and domestic supply; trade direction not quantified here)
Domestic RoleUsed as an authorized magnesium-source constituent for dietary supplements under Anvisa rules; also used in regulated pharmaceutical/technical applications
Risks
Regulatory Compliance HighNon-compliance with Anvisa’s dietary supplement framework can block market access: magnesium oxide must be an authorized constituent for supplements and must meet identity/purity/composition specifications from accepted references; failures can lead to import refusal, commercialization blocks, or enforcement actions.Verify magnesium oxide is used within the authorized-constituent framework and applicable limits; align specifications to accepted references (e.g., Farmacopeia Brasileira) and retain complete technical documentation (CoA, specs, labeling/composition justification) before shipment.
Documentation Gap MediumOperational changes to Anvisa participation and LPCO/LI models in Portal Único Siscomex (including schedule changes and temporary integration suspensions) can cause filing errors, duplicated submissions, or clearance delays if importers follow outdated instructions.Track the latest Anvisa and Siscomex notices for the correct LPCO model and submission route; use a broker checklist and pre-arrival document validation.
Quality MediumFailure to meet recognized identity/purity/assay expectations (e.g., pharmacopoeial monograph parameters used as a reference) can trigger rejection by buyers, non-conformity findings, or rework/scrap during manufacturing.Require supplier CoA with assay/purity testing aligned to an accepted reference and perform incoming QC verification on critical parameters.
Logistics MediumFreight and port delays can disrupt production schedules for supplement manufacturers relying on imported bulk mineral powders, increasing working capital and risk of stockouts.Hold safety stock, diversify approved suppliers, and contract shipments with buffer lead times during peak congestion periods.
FAQ
Magnesium oxide is it an authorized magnesium source for dietary supplements in Brazil?Yes. Instrução Normativa (IN) nº 28/2018 lists “óxido de magnésio” among authorized magnesium constituents for use in dietary supplements, and RDC nº 243/2018 restricts supplement constituents to those listed in the IN annexes.
Which specification references can be used to demonstrate identity and purity for magnesium oxide used in supplements in Brazil?RDC nº 243/2018 states that nutrient-source ingredients must meet identity, purity, and composition specifications in at least one accepted reference, including the Farmacopeia Brasileira (and other listed references). The Farmacopeia Brasileira monograph for magnesium oxide is available via Anvisa’s digital library.
Why can import clearance timelines change for food-related petitions involving Anvisa in Brazil?Anvisa and Siscomex periodically update operational procedures for Portal Único processes (including LPCO/LI models and system integrations). For example, official notices describe temporary changes in Anvisa integration with Portal Único for food imports and updates to LPCO models for Anvisa food import petitions.